Source: Pharmacy Times articles
In the results, 31% of patients maintained undetectable measurable residual disease 4 years after treatment.
Read More
Recent Content
- BRCA variants increase risk for multiple myeloma, particularly at younger age
- Carfilzomib, Lenalidomide, and Dexamethasone: A Curative Approach for Smoldering Multiple Myeloma
- Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation
- Dexamethasone benefits in multiple myeloma ‘fade into oblivion’ after a couple months
- Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity
- Maintenance combination extends PFS in newly diagnosed multiple myeloma
- Advances in CAR T-Cell Therapy and Bispecifics for Relapsed/Refractory Multiple Myeloma
- myeloMATCH to use genomics to enroll patients into target-based leukemia trials
- The Pharmacist’s Role on the Multiple Myeloma Care Team Can Vary Among Cancer Centers When Treating Patients With Bispecifics
- Robust anti-myeloma effect of TAS0612, an RSK/AKT/S6K inhibitor, with venetoclax regardless of cytogenetic abnormalities